Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Stopped early · Phase 3

Conditions studied: Chronic Lymphocytic Leukemia

In brief

The primary objective of this study is to evaluate the effect of the addition of idelalisib to ofatumumab on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL).

Key facts

Study ID
NCT01659021
Run by
Gilead Sciences
People needed
261
Starts
2012-12-04
Expected to finish
2018-08-15
Last updated by the study team
2019-08-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.